Wutah pendapatan taun lumaku: Kintara Pharma (KTRA)

Logo perusahaan publik kintara.com (KTRA)

Kintara Therapeutics (KTRA) is developing anti-tumor agents through partnerships with medical centers and strategic M&A. The laboratory search for new formulas is accelerating through the implementation of robotic screening. The current year-over-year sales trend over 12 months demonstrates revenue dynamics, where 0.00 captures the current value of the indicator. A merger with a cell therapy platform helps the company diversify its clinical risks.

Kintara Therapeutics (KTRA): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 18.11.2026

Kintara Therapeutics - rincian analitis lan metrik utama (KTRA)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Kintara
Produk merek Kintara Pharma

This indicator measures the revenue growth rate over the last four quarters relative to the previous year, neutralizing seasonal fluctuations to identify the net direction of business development. For Kintara Therapeutics (KTRA), which focuses on developing therapies for rare oncological diseases, this metric reflects the commercial efficiency of its scientific activities, as clearly evidenced by the 12-month annual revenue trajectory.

Karo sapa Kintara Therapeutics saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Monopar Pharma MNPR|Wutah pendapatan YoY sajrone 12 wulan kepungkur INBX|Wutah pendapatan taun lumaku I-Mab Biopharma IMAB|Wutah pendapatan YoY sajrone 12 wulan kepungkur FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Nuvectis Pharma, Inc. - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CHRS (Coherus BioSciences)|Corbus Pharma - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur CRDF (cardiffoncology.com)|BYSI: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku BioAtla Corp (BCAB)|Wutah dodolan YoY sajrone rolas wulan kepungkur Lixte Biotechnology Holdings, Inc.|CTXR: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) CLRB|Wutah dodolan YoY (TTM) BioLineRx Corporation (BLRX)|Wutah dodolan YoY sajrone rolas wulan kepungkur Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Wutah dodolan taun lumaku|KZIA: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku Silexion Therapeutics|NuCana plc (NCNA) - Wutah dodolan YoY sajrone rolas wulan kepungkur|Wutah pendapatan YoY sajrone 12 wulan kepungkur Chimerix, Inc|Wutah pendapatan YoY sajrone 12 wulan kepungkur CYCC|Wutah pendapatan YoY sajrone 12 wulan kepungkur G1 Therapeutics (GTHX)|Wutah dodolan YoY sajrone rolas wulan kepungkur Kronos Bio Corporation (KRON)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur